Partnerships Press Releases

12.08.2015

BIOATLA ENTERS INTO STRATEGIC LICENSE AND OPTION AGREEMENT WITH PFIZER FOR A NEW CLASS OF ANTIBODY THERAPEUTICS

12.08.2015

Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program

11.30.2015

HEPTARES ENTERS STRATEGIC DRUG DISCOVERY COLLABORATION WITH PFIZER INC. FOCUSED ON GPCR TARGETS ACROSS MULTIPLE THERAPEUTIC AREAS

11.30.2015

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

11.18.2015

Thermo Fisher Scientific Signs Development Agreement for Next-Generation Sequencing-Based Companion Diagnostic

11.10.2015

Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors

10.29.2015

GLYCOMIMETICS, INC. ANNOUNCES INITIATION OF FIRST CLINICAL TRIAL EVALUATING SUBCUTANEOUS ADMINISTRATION OF RIVIPANSEL

10.29.2015

HALOZYME ANNOUNCES FIRST CLINICAL DOSING OF PFIZER’S RIVIPANSEL USING ENHANZE™TECHNOLOGY

10.13.2015

Pelago Bioscience grants Pfizer Inc. license to the CETSA™ method

09.24.2015

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

09.09.2015

Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis

09.09.2015

GPCR Consortium Exceeds Goal with Addition of Four New Pharma Members